Kintor Pharmaceutical (HKG:9939) completed the enrollment of the first subject in the phase 3 stage pivotal clinical trial of its KX-826 tincture 1% for treating male adult hair loss, specifically the androgenetic alopecia, in China.
The trial is a multi-center, randomized, double-blind, vehicle-controlled study and adopts a 2-in-1 design for the evaluation of efficacy and safety of KX-826 tincture 1.0% for the treatment of hair loss, a Monday Hong Kong bourse filing said.
The phase 3 trials are expected to enroll 666 patients in China within five months in 25 clinical research centers in the country.
The trial comprises a 24-week treatment phase followed by a month of safety observation, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。